2-甲基蝶啶 | 2432-20-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 中文名称: 2-甲基蝶啶
• 英文名称: 2-methyl-pteridine
• 英文别名: 2-Methyl-pteridin；methylpteridine；2-Methylamino-pteridin；2-Methylpteridin；2-Methylpteridine
• CAS: 2432-20-4
• 化学式: C₇H₆N₄
• 分子量: 146.151
• InChiKey: BIGRRCHSUAXSEE-UHFFFAOYSA-N

物化性质

• 熔点：
  140°C
• 沸点：
  255.75°C (rough estimate)
• 密度：
  1.2955 (rough estimate)
• 溶解度：
  0.76 M

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  51.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-甲基蝶啶 、 乙酰乙酸乙酯 以 二甲基亚砜 为溶剂， 生成 2,7-dimethyl-5,5a,8a,9-tetrahydro-furo[2,3-g]pteridine-8-carboxylic acid ethyl ester
  参考文献：
  名称：

  Albert,A.; Mizuno,H., Journal of the Chemical Society. Perkin transactions I, 1973, p. 1974 - 1980

  摘要：

  DOI：
• 作为产物：
  描述：

  6-氯-2-甲基-5-硝基嘧啶-4-胺 在 甲醇 、 sodium hydroxide 、 sodium hydrogensulfide 、 镍 作用下， 生成 2-甲基蝶啶
  参考文献：
  名称：

  Albert et al., Journal of the Chemical Society, 1954, p. 3832,3833

  摘要：

  DOI：

文献信息

• HETEROBICYCLIC COMPOUNDS
  申请人：Amgen Inc.

  公开号：US20130225552A1

  公开（公告）日：2013-08-29

  Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.

  Formula (I)的杂环化合物： 或其药用可接受的盐、互变异构体或立体异构体，如规范中所定义，并含有它们的组合物，以及制备这种化合物的方法。本文还提供了通过抑制PDE10来治疗由此可治疗的疾病或疾病的方法，如肥胖症、非胰岛素依赖型糖尿病、精神分裂症、躁郁症、强迫症、亨廷顿病等。
• [EN] COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND USES THEREOF IN MEDICINE<br/>[FR] COMPOSÉS EN TANT QU'INHIBITEURS DU VIRUS DE L'HÉPATITE C (VHC) ET LEURS UTILISATIONS EN MÉDECINE
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2015197028A1

  公开（公告）日：2015-12-30

  Provided herein are compounds of Formula (I), or a stereoisomer, a geometric isomer, an enantiomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which are used in the treatment of HCV infection or hepatitis C. Provided herein also are pharmaceutical compositions containing such compounds and methods of using the compound of the present invention or pharmaceutical compositions thereof to treat HCV infection or hepatitis C.

  本文提供了式（I）的化合物，或其立体异构体、几何异构体、对映体、互变异构体、N-氧化物、水合物、溶剂合物、代谢物、药学上可接受的盐或其前药，用于治疗HCV感染或丙型肝炎。本文还提供了含有这些化合物的药物组合物以及使用本发明的化合物或其药物组合物治疗HCV感染或丙型肝炎的方法。
• AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES
  申请人：OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES"

  公开号：US20170183318A1

  公开（公告）日：2017-06-29

  The present invention relates to medicine and includes a method for preventing and treating diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula I or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by RNA- and DNA-containing viruses, said compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. The invention addresses the object of providing a novel agent effective in the treatment of diseases caused by an RNA-containing virus belonging to the Enterovirus, Metapneumovirus, Pneumovirus, Respirovirus, or Alfa-coronavirus genus, and/or by a DNA-containing virus belonging to the Adenoviridae and/or Herpesviridae family, and in the prevention and treatment of asthma exacerbation, chronic obstructive pulmonary disease, mucoviscidosis, conjunctivitis, gastroenteritis, hepatitis, myocarditis; in the prevention and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia, or airway obstructive syndrome.

  本发明涉及医学，包括一种用于预防和治疗由RNA-和DNA-含病毒引起的疾病以及相关疾病的方法，其中该方法包括使用通式I的化合物或其药用可接受盐的有效量。该发明还涉及制备上述化合物的方法，用于预防或治疗由RNA-和DNA-含病毒引起的疾病的药物组合物，该组合物包括通式I的化合物或其药用可接受盐的有效量。该发明解决了提供一种新型药剂的目标，用于治疗属于肠病毒、副呼吸道病毒、呼吸道病毒、呼吸道病毒或阿尔法冠状病毒属的RNA-含病毒引起的疾病，和/或属于腺病毒科和/或疱疹病毒科的DNA-含病毒引起的疾病，并在预防和治疗哮喘急性发作、慢性阻塞性肺疾病、黏液囊病、结膜炎、胃肠炎、肝炎、心肌炎；在预防和治疗流涕、急性和感染性鼻炎、咽炎、鼻咽炎、扁桃体炎、喉炎、喉气管炎、喉气管支气管炎、支气管炎、支气管炎、肺炎或气道梗阻综合征方面具有有效性。
• New utilities of tricyclic compounds
  申请人：Ishizuka Natsuki

  公开号：US20080318958A1

  公开（公告）日：2008-12-25

  Pharmaceutical compositions for enhancing the expression of apoAI are provided, which are used as medicaments for treatment of cardiovascular diseases on the basis of improving the functions of HDL. Pharmaceutical compositions for enhancing the expression of apoAI which comprises a compound of formula (I): in which X 1 and X 1 are independently an aryl or heteroaryl that may be optionally substituted, a hydrogen, a halogen, or the like; ring A is a benzene ring or 6-membered aromatic heterocyclic ring containing 1 to 3 N atoms that may be optionally condensed with another aromatic ring; R 1 to R 4 are independently a hydrogen, a halogen, a lower alkyl, a lower alkoxy or the like; a prodrug thereof, a pharmaceutically acceptable salt or solvate of them are disclosed.

  提供用于增强apoAI表达的药物组合物，用于改善HDL功能，作为治疗心血管疾病的药物。药物组合物用于增强apoAI表达，其中包括式(I)的化合物：其中X1和X2独立地是芳基或杂芳基，可以选择性地被取代，氢，卤素等；环A是苯环或含有1至3个N原子的6元芳杂环，可以选择性地与另一个芳香环融合；R1至R4独立地是氢，卤素，低碳基，低碳氧基或类似物；其前药，药学上可接受的盐或溶剂也被披露。
• TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：US20150299146A1

  公开（公告）日：2015-10-22

  The compound represented by formula (1): wherein R 4 and R 5 each represents a hydrogen atom, a halogen atom, or a C1-C3 alkyl group; R 6 represents a C1-C4 alkyl group, a C3-C6 cycloalkyl group, or the like; R 7 , R 8 , and R 9 each represents a hydrogen atom, a halogen atom, or the like; R 10 represents a C1-C3 alkyl group, or the like; R 13 represents a C1-C3 alkyl group, or the like; and Q represents a phenyl group, or the like; has an excellent control effect on pests.

  式(1)所代表的化合物：其中，R4和R5分别表示氢原子、卤素原子或C1-C3烷基；R6表示C1-C4烷基、C3-C6环烷基或类似物；R7、R8和R9分别表示氢原子、卤素原子或类似物；R10表示C1-C3烷基或类似物；R13表示C1-C3烷基或类似物；Q表示苯基或类似物。该化合物对害虫有极好的控制效果。

表征谱图